Actavis in Asia
Singapore is home to Actavis’ Asia Pacific-Africa (APACA) regional headquarters, which were formally opened on 3 April 2014.
Actavis has chosen Singapore as the location for its new regional headquarters because of its business-friendly environment and strong strategic location, which will help drive the Company’s geographic expansion and growth in markets throughout the region.
Singapore is also home to one of Actavis’ 30+ manufacturing facilities and the local commercial office. Formerly known as Drug Houses of Australia (DHA) the site is now being rebranded as Actavis. The company has operated in Singapore since 1969 and currently holds the leading position as manufacturer and distributor of generic medicines within the market.
Actavis maintains a strong presence in Asia Pacific, marketing products in 11 countries. The company has leading positions in Singapore, Hong Kong, Australia, Thailand and New Zealand, and is quickly growing in Vietnam and Malaysia. The company has manufacturing facilities in Singapore, Indonesia and Thailand.
In 2013, Actavis launched more than 70 new products and filed more than 85 applications for new products within the region. Actavis is focused on further strengthening its position in Asia Pacific by leveraging the Company’s global capabilities to build a strong and diversified regional business that can provide more products to consumers in markets throughout the region.
Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
The company has commercial operations in approximately 60 countries and more than 30 manufacturing and distribution facilities around the world, including two in Asia, in Singapore and Indonesia.